866-997-4948(US-Canada Toll Free)

Recentin (Ovarian Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Ovarian Cancer

No. of Pages : 32 Pages

 

GlobalDatas pharmaceuticals report, Recentin (Ovarian Cancer) Analysis and Forecasts to 2020 provides Recentin sales estimates for US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, and EU5 (six major markets)
  • Analysis and review of Recentin including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Recentin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2015-2020 for Recentin in the six major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Report Guidance 7


3 Ovarian Cancer: Market Characterization 8
3.1 Ovarian Cancer Market 8
3.2 Ovarian Cancer Market Forecasts and CAGR 8
3.3 Drivers for Ovarian Cancer Market 9
3.3.1 High Incidence 9
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11
3.3.4 Emergence of Targeted Drugs 11
3.3.5 Recurrence of Tumor 11
3.3.6 Low Initial Diagnosis Rate 11


4 TumorNodeMetastases (TNM) Classification of Ovarian Cancer 12


5 Recentin (cediranib) 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Factors Affecting Sales of Recentin 16
5.4.1 Limited Treatment Options 16
5.4.2 Oral Administration 16
5.4.3 Low Relative Efficacy 16
5.5 Drug Evaluation 16
5.5.1 Drug Risk Benefit Score 16
5.5.2 Intensity of Competition 17
5.6 Sales Forecasts 17
5.6.1 Target Patient Pool of Recentin 17
5.6.2 Dosing 18
5.6.3 Market Penetration 18
5.6.4 Annual Cost of Therapy 19
5.6.5 Sales Forecasts of Recentin 20


6 Ovarian Cancer Market: Appendix 28
6.1 Market Definitions 28
6.2 List of Abberiviations 28
6.3 Research Methodology 28
6.3.1 Coverage 28
6.3.2 Secondary Research 28
6.3.3 Forecasting 29
6.3.4 Number of Patients Approved to take the Drug 29
6.3.5 Net Penetration of Drug 29
6.3.6 Net Annual Dosing 30
6.3.7 Annual Cost of Therapy 30
6.3.8 Primary Research 31
6.3.9 Expert Panels 31
6.4 Contact Us 31
6.5 Disclaimer 31
6.6 Sources 32

List of Table


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Table 3: Detailed TNM Classification 13
Table 4: Drug Risk Benefit Score of Recentin 16
Table 5: Recentin, Ovarian Cancer, Global, Annual Cost of Therapy ($), 2016 19
Table 6: Recentin, Ovarian Cancer, US and EU5, Sales Forecasts ($m), 20162020 20
Table 7: Recentin, Ovarian Cancer, The US, Sales Forecasts ($m), 20172020 21
Table 8: Recentin, Ovarian Cancer, UK, Sales Forecasts ($m), 20162020 22
Table 9: Recentin, Ovarian Cancer, France, Sales Forecasts ($m), 20162020 23
Table 10: Recentin, Ovarian Cancer, Germany, Sales Forecasts ($m), 20162020 24
Table 11: Recentin, Ovarian Cancer, Italy, Sales Forecasts ($m), 20162020 25
Table 12: Recentin, Ovarian Cancer, Spain, Sales Forecasts ($m), 20162020 26

List of Chart


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 20082030 9
Figure 4: Oncology, Worldwide, Incidence (in million), 20082030 10
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 20082030 10
Figure 6: Broad Classification of Ovarian Cancer 12
Figure 7: Classification of Ovarian Cancer 14
Figure 8: Drug Model Diagram of Recentin 18
Figure 9: Recentin, Ovarian Cancer, US and EU5, Sales Forecasts ($m), 20162020 20
Figure 10: Recentin, Ovarian Cancer, The US, Sales Forecasts ($m), 20172020 21
Figure 11: Recentin, Ovarian Cancer, UK, Sales Forecasts ($m), 20162020 22
Figure 12: Recentin, Ovarian Cancer, France, Sales Forecasts ($m), 20162020 23
Figure 13: Recentin, Ovarian Cancer, Germany, Sales Forecasts ($m), 20162020 24
Figure 14: Recentin, Ovarian Cancer, Italy, Sales Forecasts ($m), 20162020 25
Figure 15: Recentin, Ovarian Cancer, Spain, Sales Forecasts ($m), 20162020 26
Figure 16: Recentin, Ovarian Cancer, US and EU5, Sales Distribution (%), 2020 27
Figure 16: Drug Model Diagram 30
Figure 17: Patients Approved for the Drug 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *